MedTrace Logo

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

NCT00958152 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-01-07

No results posted yet for this study

Summary

The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.

Conditions

  • Hepatitis C

Interventions

DRUG

VCH-222

Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37

DRUG

VCH-222

Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37

DRUG

VCH-222

Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37

DRUG

telaprevir

Tablet, Oral, 1125 mg, q12h, Days 18-37

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Vertex Pharmaceuticals Incorporated

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958152 on ClinicalTrials.gov